Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article
Metrics: PDF 524 views | HTML 1620 views | ?
Victor I. Seledtsov1 and Galina V. Seledtsova2
1lmmanuel Kant Baltic Federal University, Kaliningrad, Russia
2Institute for Fundamental and Clinical Immunology, Novosibirsk, Russia
Victor I. Seledtsov, email: email@example.com
Keywords: therapeutic antibody; antibody-mediated cytotoxicity; immune complex; tumor destruction
Received: April 25, 2018 Accepted: October 06, 2018 Published: November 06, 2018
We propose a novel immunotherapeutic paradigm that justifies application of several antibodies to various membrane-associated antigens to achieve a critical threshold density of immune complexes on the surface of cancer cells sufficient for triggering downstream cytolytic pathways. Indeed, some cancer-associated antigens (such as cancer/testis antigens) were found to be expressed on many cancer (but not normal) cells, with their baseline membrane expression levels being originally quite low for some of them, or even further down-regulated due to immune-driven cell selection. To achieve the mandatory threshold density of membrane-associated immune complexes on malignant cells, the concept stipulates combined application of antibodies specific for a cancer-associated antigen along with antibodies against an antigen expressed not only on tumor, but also on normal cells. In the proposed scenario it is of vital importance that the latter antibodies should be applied in suboptimal dosage to exclude the destruction of normal cells devoid of a cancer-associated antigen. Malignant cells often co-express antigens not present concurrently on normal cells at high levels. In such cases, suboptimal dosages of antibodies specific for those antigens could also be applied to achieve cumulative effect leading to selective destruction of tumour cells. Hence, the described immunotherapeutic technology could be used metaphorically speaking as a kind of ‘immunological knife’, which is capable of highly selective destruction of cancer cells without destroying normal cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.